Company Focus
argenx
Latest argenx News
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Related News
Insights
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.
Latest News & Features of interest to argenx
Pharmaceutical
Bensheim-based medical cannabis specialist Avextra has announced a strategic partnership with fellow German firm SynQube. 20 June 2024
Pharmaceutical
Spanish plasma-derived products specialist Grifols announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corp. 20 June 2024
Pharmaceutical
Midsize Japanese drugmaker Otsuka Pharmaceuticals says it has concluded an expanded licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen with Ionis Pharmaceuticals to cover the development and sales area to the Asia-Pacific region, including Japan. 20 June 2024
Biotechnology
The European Commission has granted marketing authorization for Altuvoct (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A. 19 June 2024
Pharmaceutical
CNS disorder specialist Intra-Cellular Therapies has announced positive to-pline results from Study 502, evaluating its depression candidate lumateperone. 19 June 2024
Biotechnology
Boston, USA-based biotech start-up Ascidian Therapeutics yesterday announced a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases, adding to the Swiss pharma giant’s plethora of RNA alliances. 19 June 2024
Biotechnology
US biotech Arvinas has promoted Ian Taylor to president of R&D. Angela Cacace will take over from Dr Taylor in his current role of chief scientific officer. 18 June 2024
Pharmaceutical
Marinus Pharmaceuticals has announced topline results showing partial success in the Phase III RAISE trial. 18 June 2024
Pharmaceutical
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Biotechnology
US liver disease focused biotech Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares leap 15.4% to $29.90 by close of trading on Monday, as it reported interim results from two Phase IIb studies evaluating volixibat. 18 June 2024
Latest In Brief for argenx
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
12 November 2024
30 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze